TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9819296

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg twice daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.50 mg twice daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 1.0 mg twice daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (all doses)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 8569263

Group type: EXPERIMENTAL
Intervention: Xiang Cheng San (HM group)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Western drugs (WM group)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Xiang Cheng San (animal experiments)
Number of subjects: 162
Study: 2505630

Group type: EXPERIMENTAL
Intervention: alfentanil-propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: alfentanil-methohexital
Number of subjects: 50

Group type: COMPARATOR
Intervention: alfentanil-etomidate
Number of subjects: 50
Study: 799569

Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 15
Study: 29621901

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 400 mg/day)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Lamotrigine and Placebo
Number of subjects: 276
Study: 28607888

Group type: EXPERIMENTAL
Intervention: Cold Dissection (CD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Monopolar-Bipolar Dissection (MBD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Coblation Dissection (CBD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: All Techniques (CD, MBD, CBD)
Number of subjects: 103
Study: 26048144

Group type: EXPERIMENTAL
Intervention: Multifaceted immunotherapeutic approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 0
Study: 23932774

Group type: EXPERIMENTAL
Intervention: Fatiguing treadmill running
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (non-injured)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ankle sprain copers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ankle instability group
Number of subjects: 57
Study: 21918063

Group type: EXPERIMENTAL
Intervention: Fortified choco-malt beverage powder (40 g daily for 120 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Matched energy equivalent unfortified placebo (40 g daily for 120 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 300
Study: 18312044

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Quetiapine (100-800 mg/day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-4 mg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: N/A (control group not specified)
Number of subjects: 400
Study: 16176847

Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA followed by MVA.HIVA (prime-boost)
Number of subjects: 35
Study: 14602793

Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v.) in normal women (NW)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v.) in obese women (OB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ghrelin response comparison between OB and NW
Number of subjects: 16
Study: 11324210

Group type: EXPERIMENTAL
Intervention: Narrow-diameter self-tapping implants (3.25-mm)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard-diameter self-tapping implants (3.75-mm)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (Narrow-diameter and Standard-diameter)
Number of subjects: 55
Study: 9621865

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study: 7838777

Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AVID study
Number of subjects: 0
Study: 3076661

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine (2.5-20 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine (twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nisoldipine (active drug)
Number of subjects: 24
Study: 1467049

Group type: EXPERIMENTAL
Intervention: Prolonged high intensity exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 321076

Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Metronidazole (after infection)
Number of subjects: 46
Study: 31490292

Group type: EXPERIMENTAL
Intervention: Superior trunk block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interscalene block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Superior trunk block
Number of subjects: 80
Study: 28503777

Group type: EXPERIMENTAL
Intervention: 8000 PNU/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6000 PNU/mL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: >8000 PNU/mL
Number of subjects: 20
Study: 25182544

Group type: EXPERIMENTAL
Intervention: Ecallantide 10 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ecallantide 30 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ecallantide 60 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 24445367

Group type: EXPERIMENTAL
Intervention: TDF co-administered with lopinavir/ritonavir (LPV/r)
Number of subjects: 741

Group type: COMPARATOR
Intervention: TDF co-administered with nevirapine (NVP)
Number of subjects: 741
Study: 22468897

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19948614

Group type: EXPERIMENTAL
Intervention: Enemas
Number of subjects: 90

Group type: COMPARATOR
Intervention: PEG (1.5 g/kg per day for 6 days)
Number of subjects: 90
Study: 17515461

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 4783

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 4783
Study: 15062908

Group type: EXPERIMENTAL
Intervention: Genetic counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11919478

Group type: EXPERIMENTAL
Intervention: Pulsatile flow detection (PFD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional color Doppler (CCD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional color Doppler (CCD) in group B
Number of subjects: 31
Study: 9679846

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 microg once daily for 2 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo spray (once daily for 2 weeks)
Number of subjects: 121
Study: 7982695

Group type: EXPERIMENTAL
Intervention: Intensive case management provided by an assertive community treatment team
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intensive case management provided by individual case managers
Number of subjects: 105

Group type: COMPARATOR
Intervention: Referral to a community mental health center
Number of subjects: 105
Study: 2686995

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 4237796

Group type: EXPERIMENTAL
Intervention: 250 mg tetracycline hydrochloride twice daily for three months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 51
Study: 31523801

Group type: EXPERIMENTAL
Intervention: Bilateral quadratus lumborum block (40 ml levobupivacaine 0.25%)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham block (control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bilateral quadratus lumborum block
Number of subjects: 86
Study: 30943426

Group type: EXPERIMENTAL
Intervention: 20-day dual n-back training following aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20-day dual n-back training following reading
Number of subjects: 0
Study: 28703374

Group type: EXPERIMENTAL
Intervention: Machine Perfusion (MP)
Number of subjects: 141
Study: 25270273

Group type: EXPERIMENTAL
Intervention: AR‐13324 ophthalmic solution 0.01%
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AR‐13324 ophthalmic solution 0.02%
Number of subjects: 224

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 224
Study: 23254324

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wound infusion catheter (WIC)
Number of subjects: 34
Study: 21598351

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: tirofiban (high-dose bolus 25 μg/kg plus 12-hr infusion 0.15 μg/kg/min)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: bivalirudin
Number of subjects: 383

Group type: COMPARATOR
Intervention: tirofiban
Number of subjects: 383
Study: 19933933

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12152

Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 12152
Study: 16784086

Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic
Number of subjects: 242

Group type: COMPARATOR
Intervention: CE-SAV
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Mosaic
Number of subjects: 242
Study: 15321995

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine IPTp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10866899

Group type: EXPERIMENTAL
Intervention: 60%-70% N(2)O in oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50% air in oxygen (control group)
Number of subjects: 30
Study: 9110076

Group type: EXPERIMENTAL
Intervention: Alternating regimen of zidovudine and didanosine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Simultaneous regimen of zidovudine and didanosine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 38
Study: 1530680

Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA placebo
Number of subjects: 0
Study: 3925488

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31801490

Group type: EXPERIMENTAL
Intervention: Pre‐oral carbohydrate load (preOp™)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard pre‐operative fasting
Number of subjects: 60
Study: 29338801

Group type: EXPERIMENTAL
Intervention: Training on nutrition, hygiene, and food safety (21-day program)
Number of subjects: 179
Study: 27463120

Group type: EXPERIMENTAL
Intervention: Interactive Internet platform for older people, used for 8 weeks.
Number of subjects: 41
Study: 26212891

Group type: EXPERIMENTAL
Intervention: Transperitoneal robot-assisted laparoscopic radical prostatectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Extraperitoneal robot-assisted laparoscopic radical prostatectomy
Number of subjects: 120
Study: 23743487

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 475
Study: 20229377

Group type: EXPERIMENTAL
Intervention: Peer-group intervention for universal precautions and teaching skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention control
Number of subjects: 0
Study: 18063490

Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (LD-HRT) containing 1mg estradiol + 0.5 mg norethisterone acetate
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Ultra low dose hormone replacement therapy (Ultra-LD-HRT) containing 0.5 mg of 17beta-estradiol and 0.25 mg of norethisterone acetate
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group receiving only 1000 mg of calcium per day
Number of subjects: 1000
Study: 16896912

Group type: EXPERIMENTAL
Intervention: Rituximab added to high-dose therapy (HDT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no rituximab)
Number of subjects: 93
Study: 14504150

Group type: EXPERIMENTAL
Intervention: Desflurane/nitrous oxide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide
Number of subjects: 50
Study: 10536546

Group type: EXPERIMENTAL
Intervention: Size 5 LMA in males
Number of subjects: 40

Group type: COMPARATOR
Intervention: Size 4 LMA in males
Number of subjects: 40

Group type: COMPARATOR
Intervention: Size 4 LMA in females
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Size 5 LMA in females
Number of subjects: 40
Study: 8603758

Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 0.5 mg x kg⁻¹ x min⁻¹
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 1.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 2.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 4.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: A balanced amino acid solution infused at 6.0 mg x kg⁻¹ x min⁻¹
Number of subjects: 8
Study: 1744374

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7024866

Group type: EXPERIMENTAL
Intervention: Diflunisal (750 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31512024

Group type: EXPERIMENTAL
Intervention: Harmonic Focus Ultrasonic Scalpel (UCSD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ligasure Small Jaw Bipolar Device (EBVS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both UCSD and EBVS
Number of subjects: 100
Study: 27760701

Group type: EXPERIMENTAL
Intervention: Continuation of specialized treatment for a total of five years
Number of subjects: 83

Group type: COMPARATOR
Intervention: Discontinuation after the standard two-year treatment
Number of subjects: 83
Study: 25242460

Group type: EXPERIMENTAL
Intervention: Pinless navigation system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional alignment jigs
Number of subjects: 80
Study: 22843310

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a 980-nm diode-laser at 300 mW for 180 seconds (54 J) applied intraorally and extraorally immediately after surgery and at 24 hours.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no LLLT) received only routine management.
Number of subjects: 30
Study: 21958233

Group type: EXPERIMENTAL
Intervention: 24-week intervention based on social-cognitive constructs including face-to-face sessions, telephone follow-ups, and use of a pedometer
Number of subjects: 92
Study: 19456797

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Number of subjects: 10
Study: 16863608

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg once daily for 9 months)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (1 day before procedure and until 9 months follow-up)
Number of subjects: 360
Study: 12623291

Group type: EXPERIMENTAL
Intervention: Tenidap 40 mg
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg
Number of subjects: 665

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Tenidap 40 mg and Tenidap 120 mg
Number of subjects: 665
Study: 10837286

Group type: EXPERIMENTAL
Intervention: High isoflavone diet (128.7 mg/d)
Number of subjects: 13
Study: 1441728

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A liposome vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of vaccine on the same day in one injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis A virus incorporated into liposomes
Number of subjects: 0
Study: 3828091

Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU retinol acetate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31714353

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30464447

Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (ECT)
Number of subjects: 6
Study: 27585745

Group type: EXPERIMENTAL
Intervention: 12 mg iron daily (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 mg or 0 mg iron daily based on weekly hepcidin screening (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 mg or 0 mg iron daily based on weekly hepcidin screening (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Universal supplementation (control group not explicitly mentioned)
Number of subjects: 0
Study: 24439986

Group type: EXPERIMENTAL
Intervention: TAPT (DAPT plus 3-month cilostazol use, n = 316)
Number of subjects: 630

Group type: COMPARATOR
Intervention: DAPT (aspirin and clopidogrel for 12 months, n = 314)
Number of subjects: 630
Study: 22749688

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal standard (Propafenone)
Number of subjects: 0
Study: 20215553

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or = 30 kg/m(2))
Number of subjects: 4381

Group type: EXPERIMENTAL
Intervention: Class I obese women (BMI 30-34 kg/m(2))
Number of subjects: 4381

Group type: EXPERIMENTAL
Intervention: Overweight status in men
Number of subjects: 4381

Group type: EXPERIMENTAL
Intervention: Underweight women
Number of subjects: 4381

Group type: COMPARATOR
Intervention: BMI
Number of subjects: 4381
Study: 18751649

Group type: EXPERIMENTAL
Intervention: Training program in cognitive-behavioral pain management strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15997257

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) therapy for 30 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 mg of paracetamol
Number of subjects: 20
Study: 11922547

Group type: EXPERIMENTAL
Intervention: White wine (300 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 10612504

Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5% solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timolol maleate gel 0.5%
Number of subjects: 30
Study: 8804673

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 1593574

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg OD
Number of subjects: 102

Group type: COMPARATOR
Intervention: Piroxicam 20 mg OD
Number of subjects: 102
Study: 6703982

Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 37
Study: 30366971

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 109
Study: 30346543

Group type: EXPERIMENTAL
Intervention: Tablet-based bedside educational intervention; provided for 1 day during inpatient stay
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tablet-based bedside educational intervention
Number of subjects: 97
Study: 27183835

Group type: EXPERIMENTAL
Intervention: Straight leg raise (SLR) tensioner intervention (3 x 1 min)
Number of subjects: 67
Study: 24840045

Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.2 mg/kg/day
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.3 mg/kg/day
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: COMPARATOR
Intervention: OROS MPH (18-54 mg/day)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.1 mg/kg/day
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edivoxetine treatment
Number of subjects: 340
Study: 23180252

Group type: EXPERIMENTAL
Intervention: Resuscitation as the delivery room management default option
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comfort care as the delivery room management default option
Number of subjects: 0
Study: 19556037

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 6 key questions regarding domestic violence (DV)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control Group (CG) - 1 question concerning domestic violence (DV)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - WC rates
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control Group (CG) - WC rates
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - PC rates
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control Group (CG) - PC rates
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - psychiatric disorder prevalence
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-battered women
Number of subjects: 400
Study: 18695931

Group type: EXPERIMENTAL
Intervention: 29.3 mg THC cigarette
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 49.1 mg THC cigarette
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 69.4 mg THC cigarette
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24